1 / 6

Global Lung Cancer Therapeutics Market 2015-2019

Cancer occurs when, after undergoing cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Get access to detailed report at: http://www.researchbeam.com/global-lung-cancer-therapeutics-2015-2019-market

Florence_2012
Download Presentation

Global Lung Cancer Therapeutics Market 2015-2019

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Lung Cancer Therapeutics Market 2015-2019 Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2015 - 2019 • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@researchbeam.com

  2. Report overview Research Beam adds "Global Lung Cancer Therapeutics Market 2015-2019". The report on the Global Lung Cancer Therapeutics Industry provides a clearer view on market Trends and Growth factors of the Global Lung Cancer Therapeutics Market 2015-2019. Cancer occurs when, after undergoing cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Non-small cell lung cancer is the commonest type of lung cancer and forms almost 85-90 percent of the total cases diagnosed. It grows and spreads slowly. Smoking is considered as a major cause of lung cancer, though lung cancer also occurs in non-smokers. Non-small cell lung cancer is of three types: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Small cell lung cancers form roughly 10-15 percent of all the diagnosed cases of lung cancer. There are two types of small cell lung cancer: small cell carcinoma and combined small cell carcinoma. It can be classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer cannot be cured using current therapies available in the market. Some of the common symptoms associated with lung cancer are chest pain, persistent cough, blood in sputum, fatigue, loss of appetite, weight loss, shortness of breath, and wheezing. Both small cell lung cancer and non-small cell lung cancer are recurrent in nature, which are difficult to cure. Get access to detailed report at: http://www.researchbeam.com/global-lung-cancer-therapeutics-2015-2019-market

  3. Report overview TechNavio's analysts forecast the Global Lung Cancer Therapeutics market to grow at a CAGR of 3.83 percent over the period 2014-2019. Covered in this Report This report covers the present scenario and the growth prospects of the Global Lung Cancer Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of non-small cell lung cancer and small cell lung cancer. The Global Lung Cancer Therapeutics market is segmented based on the type of molecule used for the treatment of lung cancer, which include: • Biologics • Small molecules In addition, the market is also segmented based on the route of administration followed for the treatment of lung cancer, which include: • Oral • Parenteral TechNavio's report, Global Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

  4. Report overview Key Regions • Americas • APAC • EMEA Key Vendors • AstraZeneca • Celgene • Eli Lilly • F. Hoffmann-La Roche • Pfizer Other Prominent Vendors • Abbvie • Aetna • Agennix • Amgen • BoehringerIngelheim • Celldex • Eisai Enquire about report @: http://www.researchbeam.com/global-lung-cancer-therapeutics-2015-2019-market/enquire-about-report

  5. Table of Contents 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Disease Overview 08. Market Landscape 09. Market Segmentation by Disease Type 10. Market Segmentation by Molecule Type 11. Market Segmentation by Route of Administration 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Pipeline Portfolio 22. Key Vendor Analysis 23. Other Reports in this Series

  6. FOR MORE DETAILS Visit us at : http://www.researchbeam.com/global-lung-cancer-therapeutics-2015-2019-market • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@researchbeam.com 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States Stay With Us:

More Related